Xeris Biopharma (XERS) Q3 2026 earnings review
Xeris Biopharma raises its revenue plan, while Gvoke sales drop
Xeris Biopharma, a rare-disease and hormone drugmaker, got a big revenue lift from its expanded sales force while its second-largest medicine shrank. Total revenue climbed 44% to $107 million as Recorlev sales nearly doubled, which lifted operating profit faster than overhead costs. Chief executive John Shannon raised the full-year revenue plan to $395–405 million and said the company is "on a path to reach more than $1 billion in total revenue in 2030".
| Total revenue | $107.2M +44% from a year ago |
|---|---|
| Recorlev net revenue | $71.5M +93% from a year ago |
| Profit before interest, taxes, depreciation, and share pay | $30.8M +76% from a year ago |
| Full-year revenue outlook | Raised $12.5M middle of the range: $400M (+37%) |
⚖️ Verdict: 🟢 Bullish
The story got better because the salespeople hired in January delivered a $15 million quarterly jump in Recorlev sales, almost double the drug's usual gain. That surge allowed third-quarter cash profit to clear the company's implied second-half floor in a single quarter. Two cautions remain: a $4 million rebate charge pushed Gvoke sales down 14%, and Recorlev now makes up two-thirds of total revenue ahead of its 2028 generic patent trial.
The question now is whether Recorlev can keep adding roughly $15 million a quarter and carry the company past its 2029 generic patent freeze. One view is that new doctors and four listed patents will keep prescriptions compounding through the 2030 thyroid drug launch; the other is that generic settlements and rising trial bills will cap profit growth. Fourth-quarter Recorlev sales and the year-end Phase 3 trial start will provide the next test.
🐂 Bull Case
Expanded Sales Team Drives Record Recorlev Add
Recorlev, a medicine for high cortisol levels in patients with Cushing's syndrome, is the main growth driver for Xeris Biopharma. The rare-disease drugmaker expanded its sales force at the start of the year and said those new representatives would take six to nine months to hit their stride. Chief executive John Shannon said "our expanded commercial team moved from build to yield and delivered record referrals and new patient starts".
- Recorlev third-quarter revenue: $71.5 million, up 93% from a year ago
- Sequential revenue gain: $14.8 million from last quarter, by our math, compared with $5.6 million to $8.3 million in prior non-winter quarters
- 2030 total revenue outlook: raised to more than $1 billion, up from about $750 million
That $14.8 million jump from last quarter is nearly double the drug's prior quarterly pace, so the extra salespeople are already bringing in prescriptions. Because of this faster adoption, Shannon said "We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected".
What to watch: fourth-quarter Recorlev revenue. Another gain above $8.5 million from the prior quarter would show this faster sales pace is durable rather than a one-time backlog clear.
Revenue Growth Outpaces Sales Force Spending
Investors worried that hiring more salespeople and starting a large thyroid drug trial would eat up profit margins in the second half of the year. Xeris did spend $17.6 million more on selling and administrative overhead and $3.6 million more on research than a year ago. Yet the 44% jump in total revenue easily covered both bills.
- Selling and administrative costs: 59.8% of revenue, down 2.7 percentage points from a year ago by our math
- Cost of making the products: 11.6% of revenue, down 3.2 percentage points on higher Recorlev share
- Operating margin: 15.8%, up 6.7 percentage points from 9.1% a year ago
- Profit before interest, taxes, depreciation, and share pay: $30.8 million, up 76% from a year ago
By our math, third-quarter profit excluding one-offs and non-cash items beat the company's full second-half floor of $25.0 million by 23% with three months still left in the year. That eases the concern about runaway costs for this quarter, though research bills will climb again when the thyroid trial begins.
What to watch: fourth-quarter research and development spending. The earlier full-year plan for a $25 million annual increase leaves $25.7 million for the fourth quarter by our math, more than double the third-quarter rate.
New Patents Extend Drug Protection To 2043
Xeris relies on patents to keep cheaper generic copies from taking over its specialty medicines. In October, the US Patent and Trademark Office granted a new patent for Keveyis, a treatment for rare muscle paralysis, protecting the medicine through at least 2043 instead of the previously expected 2039. Regulators also issued a third US patent for XP-8121, the company's weekly thyroid injection in development, expiring in October 2043.
Keveyis revenue rose 9.1% from a year ago to $13.0 million, so longer legal protection preserves a steady cash generator while XP-8121 moves through clinical studies. What to watch: any new generic patent challenges filed against Keveyis or Recorlev in upcoming quarterly legal disclosures, which would test these new 2043 boundaries.
🐻 Bear Case
Price Rebates Cut Gvoke Sales Despite Demand
Gvoke is a ready-to-use liquid glucagon injection that treats dangerously low blood sugar. The Chicago drugmaker highlighted "stronger-than-historical back-to-school prescription demand" for the product in the third quarter. Despite that upbeat framing, reported Gvoke revenue fell 13.7% from a year ago to $21.7 million, and declined 3.7% from the second quarter.
Management said a one-time $4 million adjustment for rebates and discounts wiped out the prescription gains. Even adding back that $4 million charge, Gvoke sales grew only 2.2% from a year ago by our math, leaving nine-month sales down 6.3%. That falls well short of the high-single to low-double-digit full-year growth the company projected at the start of the year.
What to watch: fourth-quarter Gvoke net revenue and the accrued rebates balance on the balance sheet. A rebound above $24.6 million is needed just to match last year's fourth quarter and show that rebate adjustments have settled.
Recorlev Now Carries Two-Thirds Of Revenue
Recorlev's rapid growth is lifting the whole business, making it the company's strongest positive driver while also increasing its biggest single-product risk. By our math, the Cushing's syndrome medicine generated 66.7% of total revenue in the third quarter, up from 61.7% last quarter and 49.7% a year ago. Meanwhile, Gvoke and Keveyis together shrank as a share of the company.
This concentration matters because five generic drugmakers have challenged Recorlev's patents in federal court. An automatic regulatory freeze blocks generic copies until June 2029, with a court trial tentatively set for November 2028. Because XP-8121 will not launch until 2030 even if its trials succeed, Xeris depends almost entirely on winning or settling that court fight to reach its new $1 billion 2030 revenue goal.
What to watch: legal updates on the consolidated Recorlev patent lawsuit in the third-quarter filing. Any schedule shift or settlement before the November 2028 trial date will directly govern the company's main revenue stream.
Risks this quarter didn't answer
Two standing operational concerns wait for the full quarterly report, while shareholder dilution continued to climb in the background.
- Recorlev patient counts and drop-off rates: management cited record referrals and starts but gave no patient count for a third straight quarter; any disclosed number on the call would test whether price or patient volume drove the 93% jump.
- Expired inventory write-downs: not detailed in the release; the quarterly filing's inventory footnote will show whether write-down reserves kept rising above the second quarter's $13.7 million.
- Rising share count: diluted shares rose 6.9% from a year ago to 189.9 million, and total shares reached 182.7 million in October (up 10.1% from a year ago by our math) after employee stock awards and July's debt conversion.
👓 Other Themes
XP-8121 Phase 3 Trial Details Set
On September 9, Xeris outlined the clinical plan for XP-8121, its weekly under-the-skin thyroid hormone injection. The main Phase 3 study, called Cornerstone, will enroll 500 patients across more than 50 US sites for 54 weeks to test whether weekly injections match daily pills. Shannon said "We remain on track to initiate Cornerstone, our pivotal Phase 3 study, by year-end", targeting results in late 2028 and a 2030 launch.
💲 Other KPIs
Net debt — total debt minus cash — fell 55.2% from last quarter's $130.8 million by our math. In July, the biopharma group retired all $34 million of its 2028 convertible notes using cash and stock, while strong operating cash lifted cash on hand to $131.1 million and returned stockholders' equity to a positive $48.8 million.
Money owed by customers rose 27.6% from a year ago and 34.4% since December, by our math, staying well below the 44.2% jump in third-quarter revenue. Because receivables grew slower than sales, the company collected cash on time even as specialty pharmacy shipments of Recorlev expanded.
🔮 Guidance
Raised. Management lifted the middle of the full-year range by $12.5 million, calling for 37.1% annual growth. By our math, that leaves $117.5 million for the fourth quarter — up 37.0% from a year ago and 9.6% from the third quarter. It is the third raise this year, and much larger than the prior two: +$2.5M, +$2.5M, +$12.5M.
Raised. Chief executive John Shannon lifted the long-term 2030 revenue target by at least $250 million, or 33% by our math, after not mentioning the $750 million figure on earnings calls for four quarters. Management tied the higher goal to Recorlev reaching nearly $1 billion in annual sales three to four years earlier than previously planned.
❓ Key Questions
How many patients take Recorlev, and how many stay on?
Management stopped reporting exact Recorlev patient counts after ending last year at roughly 700 patients. Without knowing patient numbers or drop-off rates, investors cannot tell how much of the $14.8 million quarterly jump came from new patients versus higher doses.
Why did Gvoke need a $4 million rebate adjustment?
A one-time $4 million discount and rebate charge turned strong back-to-school Gvoke prescriptions into a 14% revenue drop. Investors need to know which payer channel caused the catch-up charge and whether the company still expects Gvoke to grow for the full year.
Did expired inventory write-downs keep rising in the third quarter?
In the first half of the year, reserves for expired and excess inventory climbed from $7.6 million to $13.7 million and took 2.9 percentage points off second-quarter gross margin. The press release omits the third-quarter reserve figure ahead of the quarterly filing.
How much will the 500-patient XP-8121 trial cost in total?
Xeris plans to enroll 500 patients for 54 weeks across more than 50 US sites starting by year-end. Management has not stated the total multi-year dollar budget for the Cornerstone study or whether third-quarter research spending of $11.1 million reflects start-up bills.